Recommended

Lilly to sell Branchburg site as its global manufacturing plans take shape
Bristol Myers Squibb names new Head of Development
Sanofi strikes $1.6 bn respiratory vaccine deal
Lilly’s Alzheimer’s drug demonstrates long-term benefit
Amid FDA turmoil Sarepta’s gene therapy worries begin to ease
Decentralised manufacturing world-first with new UK legislation
Key trends shaping the pharma landscape in Q3 2025
Transforming pharma manufacturing with digital tools
On-demand webinar

cDPI: Line extension with capsule-based inhalation drug delivery

28 February 2023

Shares

6

Watch this webinar on capsule-based dry powder inhalers (cDPI) to discover how capsules work as a unit dosage form for the inhalation-based delivery of the active pharmaceutical ingredients.

About this webinar

Drug delivery via the inhalation route is currently in demand for treatment of various diseases including asthma and chronic obstructive pulmonary disorders. It is currently the subject of intense research and development because of its prominent therapeutical benefits. Industry is working on this new approach for delivering potent drugs of biological origin.

But the questions are:

  • How do inhalation delivery systems work?
  • What are the advantages of inhalation drug delivery?
  • What are the different means to deliver your APIs?
  • What is the role of the capsules in inhalation delivery systems?

Many companies are prioritising the dry powder inhaler (DPI) system as a cornerstone for asthma and related disease. In capsule-based DPI systems capsules work as the reservoir for APIs.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The cDPI is one of the most acceptable forms of inhaler due to its simplicity and ease of handling, particularly for single dose formulations.

Join us to learn more about cDPI and how exactly the capsules work in the dry powder inhaler device. Gain closer insights into ACG’s capsule variants for DPI applications.

Key takeaways

  • Understand how exactly cDPI systems work
  • Discover the advantages of using inhalation drug delivery over oral and parenteral drug delivery for treating asthma and other COPDs
  • Explore the new application of capsules for nasal drug delivery
  • Learn more about the capsule portfolio for cDPIs.

Our speakers

Dr Jnanadeva Bhat, PhD, Head – Formulation R&D (Pharma & Nutra), ACG

Dr Bhat has been associated with the pharmaceutical industry for more than two and a half decades. As a product formulator, he has worked on various dosage forms, including tablets, soft gelatine and hard capsules, injectables and lyophilised formulations. At ACG, Dr Bhat heads the formulation R&D lab where he primarily leads new product development projects, enriching the existing portfolio. He has published several technical white papers and articles.

Dr Subhashis Chakraborty, Head of Global Product Management, ACG

Dr Chakraborty has more than 15 years of experience in diversified portfolios including R&D, business development, sales and product management. At ACG, he spearheads development of new capsule technologies for pharma and nutraceutical applications through to commercialisation. Dr Chakraborty has a PhD in Pharmaceutical Sciences from IIT, Banaras Hindu University. He has more than 40 international scientific publications and two book chapters to his credit.

Share via